Zhitong Hong Kong stocks have long known | The shortage of memory may continue until 2027, SpaceX's market value will evaporate by 225 billion US dollars

[Today's headlines]

Memory shortages may continue until 2027, Samsung, SK Hynix, and Micron sell out of production capacity ahead of schedule

According to technology media reports on Tuesday, the tight supply of memory chips is expected to continue until 2027. Industry sources revealed that the three major memory manufacturers have basically completed next year's capacity allocation negotiations. In short, Samsung, SK Hynix, and Micron's projected memory supply for 2027 have all been sold out, and there are no plans to increase production capacity.

According to the report, the three major suppliers have distributed all DRAM and HBM production capacity in 2027. The customer ended up receiving only 60% to 70% of the shipment volume they initially requested. Industry insiders pointed out that 2027 will enter the most severe phase of memory shortage. Shipment quantities have now been largely finalized, but final shipping pricing will be determined closer to delivery.

According to the latest storage spot price trend report released by TrendForce Jibang Consulting, the upward trend in DRAM spot prices has weakened since late July, and 4Gb DDR4 and 2Gb DDR3 prices have risen slightly with limited trading volume. It involves the Hong Kong stock memory chip sector.

[General outlook]

Major US technology stocks had mixed ups and downs, and SpaceX's market capitalization evaporated by 225 billion US dollars

Overnight, the US stock index rose 263.24 points to close at 54349.12 points, or 0.49%; the S&P 500 stock index fell 12.97 points to close at 7723.55 points, or 0.17%; and the Nasdaq Composite Index fell 221.55 points, to close at 26363.44 points, or 0.83%.

Major technology stocks had mixed ups and downs. SpaceX fell by more than 13%, the market capitalization evaporated by 225 billion US dollars. The total market capitalization was surpassed by Meta, AMD fell more than 7%, Google fell more than 4%, Nvidia rose more than 3%, and the daily market rose 5 times in a row, setting a new high since the beginning of June, with a total market capitalization of 5.3 trillion US dollars.

Oil and gas stocks generally fell, EOG Energy fell by more than 6%, and ConocoPhillips and Occidental Petroleum fell by more than 2%. Mining stocks surged. Eagle Mining rose nearly 10%, Jintian rose more than 9%, and Kinross Gold rose nearly 9%. PV stocks plummeted, SolarEdge fell more than 30%, and SunPower fell more than 10%.

Most popular Chinese securities fell, and the Nasdaq China Golden Dragon Index fell 1.09%. The Hang Seng Index ADR declined. On a proportional basis, it closed at 25717.11 points, down 198.71 points, or 0.77%, from the Hong Kong closing.

WTI crude oil futures on the New York Mercantile Exchange fell $0.69 for the month, to close at $75.08 a barrel, or 0.91%. COMEX gold futures rose $155.40 in the same month, or 3.74%, to $4308.0 per ounce.

[Hot Topics Preview]

Shanghai Stock Exchange: Transferring MINIMAX-W (00100), etc. to the Hong Kong Stock Exchange under the Shanghai-Hong Kong Stock Connect

The Zhitong Finance App learned that on August 5, the Shanghai Stock Exchange announced that according to the relevant provisions of the “Shanghai Stock Exchange Shanghai-Hong Kong Stock Connect Business Implementation Measures”, the Shanghai-Hong Kong Stock Connect (hereinafter referred to as Hong Kong Stock Connect) list was adjusted and transferred to MINIMAX-W (00100), Lixun Precision (02475), and Sanhuan Group (06951), which will take effect from the next Hong Kong Stock Connect trading day.

Kangfang Biology (09926): International Phase II/III study on first-line treatment of UC with evasil combined with Pfizer vintuumab begins

On August 5, Kang Fang Biotech announced that its overseas partner Summit Therapeutics, which developed the world's first PD-1/VEGF dual-antibody drug, will conduct a phase II/III international multi-center registered clinical study of evossi combined with vintuizumab compared with pabolizumab combined with EV to treat locally advanced or metastatic urothelial carcinoma on the first line. Currently, Kang Fang Biotech is responsible for promoting the Chinese research part of Harmoni-GU1, and SUMMIT is responsible for carrying out overseas research parts of Harmoni-GU1 research, including the US and Europe.

Makiyuan Co., Ltd. (02714)'s commercial pig sales revenue in July was about 8.897 billion yuan, down 23.56% year on year

According to the Zhitong Finance App, Muyuan Co., Ltd. (02714) announced that in July 2026, the company sold about 6.66 million commercial pigs, up 4.82% year on year; the average sales price of commercial pigs was about RMB 10.64 per kilogram, down 25.59% year on year; commercial pig sales revenue was about RMB 8.897 billion, down 23.56% year on year. The sales price and revenue of commercial pigs dropped significantly year-on-year, mainly affected by fluctuations in the pig market.

Dacheng Fund: Its funds will invest in shares related to Everbright Securities (06178) and Zhongtai Securities

According to Dacheng Fund's announcement, all of its Dacheng China Securities investment funds refer to securities companies' traded open index securities investment funds mainly using a complete copy method. The underlying index stocks Everbright Securities and Zhongtai Securities are shares issued by the fund manager's shareholder and fund custodian, respectively. In order to reduce tracking errors and protect the rights and interests of holders, the above stocks are included in the investment target after consultation and implementation procedures, daily investment management and regular reporting disclosure are carried out in accordance with regulations.

Yuejiang (02432) releases full-body humanoid robot Yuejiang Lu Meng

Yuejiang Technology officially released the first full-body humanoid robot, Yuejiang Lu Meng. The robot is nearly 1.3 meters tall and is equipped with its full-stack self-developed space game size model to achieve multi-modal emotion perception, three-dimensional spatial understanding and initiative, and independent learning and long-term evolution. In addition, Lumeng from Vietnam provides a personalised intelligent teaching and development platform to support secondary development, which can be used for personalised intelligent course teaching and subject research.

CSPC Group (01093) received a milestone payment of $10 million from AstraZeneca under a strategic R&D cooperation agreement

According to the Zhitong Finance App, Shiyao Group announced that the company and AstraZeneca have signed a joint venture contract to establish a joint venture to build a next-generation biologics production base in Shijiazhuang, China to further deepen strategic cooperation. According to the announcement, CSPC Group and AstraZeneca will invest 51% and 49% of the shares respectively, and jointly manage the construction and daily operation of the joint venture. The joint venture's initial business will focus on the production and supply of biologic pharmaceutical solutions (DS) agreed upon by the parties for the global market.

China Chunlai (01969) plans to acquire Dublin Business School for US$127.5 million to expand overseas higher education

Prior to the date of the share purchase agreement, a notice on the acquisition was submitted to the Irish Ministry of Enterprise, Tourism and Employment in accordance with the Irish Foreign Direct Investment Act. On July 30, 2026, the department confirmed that the acquisition was not subject to review and could be completed.

Rongchang Biotech (09995) expects net profit to be around 4.7 billion yuan in mid-2026

According to the Zhitong Finance App, Rongchang Biotech (09995) announced that it expects mid-term revenue of about RMB 5.85 billion in 2026, an increase of about 433% over the previous year. Net profit attributable to owners of the parent company in mid-2026 is estimated to be approximately RMB 4.7 billion, turning a loss into a profit compared with the same period last year.

Unified Enterprise China (00220) announced interim results, profit attributable to shareholders of 1,402 billion yuan, an increase of 8.99% year-on-year

According to the Zhitong Finance App, Unified Enterprise China (00220) announced the 2026 interim results. The group obtained revenue of RMB 17.321 billion (same unit), an increase of 1.37% over the previous year; profit attributable to the company's equity holders was RMB 1,402 million, an increase of 8.99% over the previous year; and the basic profit per share was 32.47 points.

[Individual stock prices are clear]

BeiGene (06160): Increase the 2026 revenue and other performance forecast ranges

According to the Zhitong Finance App, BeiGene (06160) announced that the company's product revenue for the 2026 semi-year was 21.797 billion yuan, up 25.6% year on year; the company's total revenue for the first half year of 2026 was 22.220 billion yuan, up 26.8% year on year; net profit attributable to parent company owners for the first half year of 2026 was 3.271 billion yuan, up 627.1% year on year. The increase in product revenue was mainly due to increased sales of Baiyuze® (zebutinib) and Amgen authorized products and Bazean® (tiralizumab).

After excluding the impact of non-cash items such as share payments, depreciation, and amortization expenses, the adjusted operating profit for the 2026 semi-year was 6.508 billion yuan, up 101.9% year on year; adjusted net profit for the 2026 semi-year was 5.863 billion yuan, up 127.0% year on year. At the end of the reporting period, the company's total assets were 62,499 billion yuan, up 9.1% from the beginning of the period; owners' equity attributable to the parent company was 35.427 billion yuan, an increase of 15.6% over the beginning of the period.

Based on strong performance, BeiGene raised its 2026 full-year results guidance. The company expects annual revenue to rise to 44.9 billion yuan to 46.2 billion yuan. Annual operating income after deducting operating costs, R&D expenses, sales and administrative expenses, taxes and surcharges (“operating costs”) will be raised to $6.5 billion to $7.1 billion; operating income after deducting adjusted operating costs will be raised to $11.5 billion to $12.2 billion.